The Global Buparlisib Market was valued at US$ 73.6 Million in 2024 and is projected to reach US$ 102.1 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period (2024–2030). This growth is being driven by increasing oncology research activities, rising demand for targeted cancer therapies, and the accelerating adoption of PI3K inhibitors in clinical and preclinical settings across academic and pharmaceutical sectors.

As the pharmaceutical industry transforms toward precision medicine and targeted therapies, the spotlight is on the key manufacturers who are driving innovation, clinical development, and novel treatment pathways. In this blog, we profile the Top 10 Companies in the Buparlisib Market—a mix of research chemical suppliers, biotechnology firms, and pharmaceutical innovators shaping the future of oncology treatment.

---

🔟 1. Selleck Chemicals

Headquarters: Houston, Texas, USA
Key Offering: Buparlisib (BKM120), Catalog-grade PI3K inhibitor

Selleck Chemicals stands as a leading global supplier of high-purity Buparlisib for research and development applications. Their pharmaceutical division serves academic institutions, contract research organizations, and biopharmaceutical companies, with specialized capabilities in providing GMP-grade materials for clinical trial applications.

Research and Development Initiatives:

• Advanced formulation technologies for improved bioavailability

• Clinical trial partnerships with oncology research centers

• Committed to expanding their oncology research compound portfolio

Download FREE Sample Report: Buparlisib Market – View in Detailed Research Report

---

9️⃣ 2. Abcam plc

Headquarters: Cambridge, United Kingdom
Key Offering: Buparlisib research grade, Antibodies for PI3K pathway analysis

Abcam operates across more than 130 countries and supplies over 10,000 research institutions globally. It is a significant player in providing high-quality research tools for investigating the PI3K/AKT/mTOR signaling pathway in cancer biology.

Research and Development Initiatives:

• Targeted cancer research reagent development

• Collaboration with academic researchers and pharmaceutical companies to advance cancer drug discovery

---

8️⃣ 3. BOC Sciences

Headquarters: Shirley, New York, USA
Key Offering: Buparlisib reference standard, Custom synthesis services

BOC Sciences’ research chemicals division is expanding its oncology portfolio with comprehensive PI3K inhibitor offerings through their specialized manufacturing capabilities.

Research and Development Initiatives:

• Analytical method development for Buparlisib characterization

• Pharmaceutical development partnerships with research institutions and CROs

---

7️⃣ 4. Cayman Chemical

Headquarters: Ann Arbor, Michigan, USA
Key Offering: Buparlisib analytical standard, Metabolite identification services

Cayman Chemical is recognized for its high-purity chemical standards and comprehensive research tools for cancer biology studies. The company maintains stringent quality control measures for all its research compounds.

Research and Development Initiatives:

• Expansion of oncology research product lines

• GMP-compliant manufacturing capabilities for clinical research applications.

Download FREE Sample Report: Buparlisib Market – View in Detailed Research Report

---

6️⃣ 5. BioVision, Inc.

Headquarters: Milpitas, California, USA
Key Offering: Buparlisib research chemical, Cell-based assay kits

BioVision’s research division delivers high-quality biochemicals and assay kits to over 5,000 research institutions worldwide. The company provides validated research tools for investigating PI3K signaling pathways in various cancer types.

Research and Development Initiatives:

• Provides certified Buparlisib for preclinical studies

• Targets expanding their oncology research portfolio with novel inhibitors

---

5️⃣ 6. Santa Cruz Biotechnology, Inc.

Headquarters: Dallas, Texas, USA
Key Offering: Buparlisib inhibitor, Antibodies for cancer research

Santa Cruz Biotechnology maintains a comprehensive portfolio of research chemicals and biological reagents for oncology studies, with particular expertise in kinase inhibitor research applications.

Research and Development Initiatives:

• Current research compound portfolio: Over 50,000 products

• Target: Development of 500 new research antibodies annually

---

4️⃣ 7. Biosynth Carbosynth

Headquarters: Staad, Switzerland
Key Offering: Buparlisib reference material, Impurity standards

Biosynth Carbosynth serves over 200 pharmaceutical companies and research institutions with high-purity research compounds. It plays a vital role in supplying reference standards for analytical method development and quality control applications.

Research and Development Initiatives:

• Custom synthesis services for Buparlisib derivatives

• R&D into novel PI3K inhibitor structures and analogs

---

3️⃣ 8. Adooq Bioscience

Headquarters: Irvine, California, USA
Key Offering: Buparlisib for research use, Pharmaceutical intermediates

Adooq Bioscience specializes in providing research-grade small molecule inhibitors, with a dedicated focus on oncology research applications and drug discovery programs.

Research and Development Initiatives:

• Proprietary compound library development

• Academic research collaborations for compound validation studies

---

2️⃣ 9. Axon Medchem

Headquarters: Groningen, Netherlands
Key Offering: Buparlisib research chemical, Analytical services

Axon Medchem maintains a specialized portfolio of research compounds for signal transduction research, particularly focusing on inhibitors of key cancer pathways including PI3K/AKT/mTOR signaling.

Research and Development Initiatives:

• Novel chemical entity development for oncology targets

• Strategic partnerships with academic research groups across Europe and North America

---

1️⃣ 10. TargetMol Chemicals Inc.

Headquarters: Boston, Massachusetts, USA
Key Offering: Buparlisib bioactive compound, Drug discovery libraries

TargetMol specializes in providing comprehensive compound libraries for drug discovery and chemical biology research, with specialized collections focused on kinase inhibitors and cancer therapeutics.

Research and Development Initiatives:

• High-throughput screening compound collections

• Collaborative research programs with pharmaceutical companies for lead compound identification

Get Full Report Here: Buparlisib Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Buparlisib is More Targeted and Effective

The Buparlisib market is undergoing a strategic evolution. While research-grade applications currently dominate volume, the industry is investing significantly in clinical development pathways, formulation technologies, and combination therapy approaches.

📈 Key Trends Shaping the Market:

• Rapid expansion of PI3K inhibitor research in academic and pharmaceutical settings

• Regulatory focus on orphan drug designations for rare cancer indications

• Digitalization of compound screening platforms and research data management

• Academic-pharmaceutical company alliances for drug repurposing studies

Get Full Report Here: Buparlisib Market – View in Detailed Research Report

The companies listed above are not only supporting global cancer research—they’re driving the precision medicine evolution in oncology therapeutics.